Pet IL-31 Therapeutic Antibody Development

Creative Biolabs specializes in developing innovative antibody therapeutics that address key drivers of disease in companion animals. Our IL-31 therapeutic antibody development program is designed to support the growing need for targeted treatments in veterinary dermatology and immune-mediated disorders. By integrating advanced discovery platforms, engineering capabilities, and preclinical validation, we empower clients to advance IL-31-focused projects into promising therapeutic solutions. If your team is exploring IL-31 antibody strategies, we encourage you to reach out and discuss collaboration opportunities with our experts.

Platforms in Therapeutic Antibody Discovery

We provide a comprehensive portfolio of discovery technologies that ensure the identification of high-quality therapeutic leads. Our flexible approach allows projects to leverage one or more platforms, depending on the desired antibody profile and therapeutic objectives.

• Phage Display: Tailored species-specific libraries enable efficient screening for high-affinity IL-31 binders that are optimized for use in dogs or cats. This approach allows rapid candidate generation while minimizing immunogenic risks.
• Single-B Cell Sorting: By isolating antigen-specific B cells, we capture natural immune responses with excellent therapeutic potential. These candidates can be engineered for enhanced stability, affinity, and pharmacokinetics.
• Hybridoma Technology: A proven tool for monoclonal antibody generation, hybridoma platforms provide stable, well-characterized clones suitable for downstream engineering and optimization.

Comprehensive Antibody Development Services

Our services are designed to guide your project seamlessly from concept through development. With these integrated services, we position our clients to advance IL-31 antibodies efficiently and confidently toward veterinary applications.

Antibody Characterization

In-depth analyses of binding specificity, affinity, and functional blocking capacity ensure therapeutic relevance.

Antibody Engineering

Structural improvements, Fc optimization, and stability enhancements create antibodies with greater efficacy and durability in vivo.

Preclinical Evaluation

We provide in vitro assays and in vivo models to assess antibody performance, safety, and translational potential for veterinary use.

Antibody Development

From candidate refinement through scalable production and regulatory documentation, Creative Biolabs supports the transition from research to application.

Discover How We Can Help - Request a Consultation

Why Focus on IL-31?

IL-31 is a pro-inflammatory cytokine produced predominantly by activated T cells and plays a central role in mediating pruritus (itching) and skin inflammation. In dogs, IL-31 is strongly associated with atopic dermatitis, one of the most prevalent chronic skin diseases in veterinary medicine. This condition leads to persistent itching, self-trauma, secondary infections, and reduced quality of life. While IL-31's role in feline dermatologic disorders is less studied, emerging evidence suggests it may contribute to allergic skin disease in cats as well. Given the significant burden of chronic pruritus in companion animals, targeting IL-31 presents a powerful therapeutic opportunity to improve comfort and long-term disease management.

Mechanism of Action

IL-31 antibodies work by binding to circulating IL-31 and preventing its interaction with the IL-31 receptor complex, which is expressed on keratinocytes, sensory neurons, and immune cells. By blocking this ligand-receptor interaction, antibody therapy interrupts downstream signaling pathways that drive itch sensation and skin inflammation. This not only reduces scratching behavior but also improves skin barrier integrity and lowers the risk of secondary bacterial or yeast infections. Through this precise targeting, IL-31 therapeutic antibodies address the root cause of pruritus rather than simply masking symptoms, offering pets more sustained relief.

Fig 1. Immunopathogenesis of canine atopic dermatitis and pharmacologic targets of anti-cytokine therapies.¹

Our Advantages

• Species-Specific Expertise: Antibodies are designed specifically for canine and feline immunology, ensuring compatibility and efficacy.
• Integrated Pipeline: Discovery, optimization, and preclinical evaluation are unified within a seamless workflow.
• Advanced Innovation: Incorporation of next-generation screening tools and structural modeling accelerates project timelines.
• Collaborative Partnership: We tailor every project to client goals, emphasizing transparency and long-term success.

Partner with Creative Biolabs

IL-31 therapeutic antibodies represent a transformative approach to managing chronic skin diseases and pruritus in companion animals. Creative Biolabs is committed to supporting researchers and industry partners in bringing these innovative therapies to the veterinary market. By combining scientific expertise with advanced platforms, we help turn promising antibody candidates into impactful treatments. Connect with Creative Biolabs today to explore how we can collaborate on IL-31 therapeutic antibody development and make a meaningful difference in pet health.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Wichtowska, Agnieszka, and Małgorzata Olejnik. "Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis." International journal of molecular sciences vol. 26,22 10990. 13 Nov. 2025. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms262210990